BRCA Gene Mutations Associated With Increased Prostate Cancer RiskCharles Richardson
From the data, the researchers estimated that men who carry a BRCA2 mutation have a 27% risk of developing prostate cancer by the time they are 80 years old, more than double the rate compared to non-carriers. BRCA1 mutations were not associated with an increase in prostate cancer risk. ...
2、brca2 前列腺癌doi:10.14033/ki.cfmr.2019.30.081 a 1674-6805(2019)30-0-03abstract family history is one of the risk factors for prostate cancer, and breast cancer susceptibility gene 2 (brca2) is a proven genetic risk factor for prostate cancer. although the role of brca2 and brca1 ...
[4]K. N. Chi et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol 2023 Sep;34(9):772-782. [5...
In addition, Genotype-Identity-by-Descent Sharing Test results suggest that Gln(356)Arg accounts (in part) for our prior evidence of prostate cancer linkage to chromosome 17q21 (P = 0.022). Thus, we have identified a common, nonsynonymous substitution in the BRCA1 gene that is associated ...
Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration Sensitive Prostate Cancer (mCSPC) (AMPLITUDE). Available at: https://clinicaltrials.gov/ct2/show/NCT04497844. Last accessed: April 2023....
or other cancer-related gene mutations that are not detected by this test. For this reason, a negative test result could still mean that a person has an increased risk of cancer due to gene mutations. Additionally, most cases of cancer are not caused by hereditary gene mutations but are tho...
[6] ESMO 2019. PROfound: Phase 3 Study of Olaparib vs. Enzalutamide or Abiraterone for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations. 作者介绍 曹漫明,南方医科大学珠江医院肿瘤科副主任医师、医学博士。...
These PCa risk estimates will assist in guiding clinical management. The study-level subgroup analyses indicate that risks may be modified by age and ethnicity, and forBRCA2carriers by PV location within the gene, which may guide future risk-estimation studies. ...
PIK3CAm,AKT1m, orPTENm125, and pembrolizumab for the treatment of unresectable or metastatic solid tumors of any type with high tumor mutational burden126may have led to an increase in patient referrals for tumor testing using a gene panel assay. An increasing number of patients with BRCAm ...